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Abstract
Background
Non-union affects up to 10% of fractures and is associated with substantial morbidity. There
is currently no single effective therapy for the treatment or prevention of non-union. Potential
treatments are currently selected for clinical trials based on results from limited animal stud-
ies, with no attempt to compare results between therapies to determine which have the
greatest potential to treat non-union.
Aim
The aim of this systematic review was to define the range of therapies under investigation
at the preclinical stage for the prevention or treatment of fracture non-union. Additionally,
through meta-analysis, it aimed to identify the most promising therapies for progression to
clinical investigation.
Methods
MEDLINE and Embase were searched from 1St January 2004 to 10th April 2017 for con-
trolled trials evaluating an intervention to prevent or treat fracture non-union. Data regarding
the model used, study intervention and outcome measures were extracted, and risk of bias
assessed.
Results
Of 5,171 records identified, 197 papers describing 204 therapies were included. Of these,
the majority were only evaluated once (179/204, 88%), with chitosan tested most commonly
(6/204, 3%). Substantial variation existed in model design, length of survival and duration of
treatment, with results poorly reported. These factors, as well as a lack of consistently used
objective outcome measures, precluded meta-analysis.
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Conclusion
This review highlights the variability and poor methodological reporting of current non-union
research. The authors call for a consensus on the standardisation of animal models investi-
gating non-union, and suggest journals apply stringent criteria when considering animal
work for publication.
Introduction
Fracture non-union can be defined as occurring when the normal healing processes of bone
cease to the extent that solid healing cannot occur without further intervention[1]. The condi-
tion is estimated to affect 5–10% of fractures[2, 3], with wide variation depending on anatomi-
cal location[4]. The negative effect on quality of life associated with non-union has been
demonstrated as being greater than that of diabetes mellitus, stroke and acquired immunodefi-
ciency syndrome[5], with substantial financial consequences[6].
The failure of a fracture to unite is multifactorial and the result of both predisposing and
contributing factors[1, 7]. There is no consensus or accepted guidelines for the treatment of
non-union, but most current management strategies involve hospital admission and revision
surgery, frequently using bone graft or synthetic substitutes, with varied and unpredictable
results. In order to either primarily prevent non-union, increase the likelihood of success of
revision surgery, or potentially offer an alternative to surgery, researchers continue to evalua-
tion novel therapies in this field.
Preclinical studies are defined as those using animals to determine if a treatment is likely to
be effective, before progression to testing in humans [8].
It is currently not clear on what basis researchers select potential therapies for translation
into clinical studies. It is likely that positive results from a single, or a small number, of animal
studies are used to justify progression to clinical trial. However, it is problematic to rely on the
positive effects of a therapy in a single animal study to justify direct translation to clinical test-
ing due to the likely existence of bias and methodological weakness. There is no evidence that
researchers in this field have compared different preclinical studies in an attempt to determine
which therapies are the most promising and therefore should be prioritised for translation into
clinical studies.
Systematic reviews summarise the literature for a defined research question; when com-
bined with a meta-analysis of results they are considered to represent the highest level in the
hierarchy of evidence[9]. Despite this, meta-analyses are reliant upon the quality of data in
the original studies included, and can risk propagating any errors included in the original
research. The methodology for systematic reviews of preclinical research is still evolving, but
it is recognised that the technique has the potential to clarify the existing evidence base and
potentially increase the precision of effect estimates through meta-analysis[10, 11]. To date
there has not been a systematic review or meta-analysis of preclinical studies aiming to prevent
or treat fracture non-union.
The aim of this systematic review was firstly to establish the range of therapies under inves-
tigation at the preclinical stage for the prevention or treatment of fracture non-union. Sec-
ondly, by conducting a meta-analysis of results of methodologically similar studies, it aimed to
systematically and objectively identify the most promising therapies for progression to clinical
investigation.
Preclinical therapies for fracture non-union
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Materials and methods
Search strategy and inclusion criteria
Full methodological details can be found in the previously published protocol[12]. The proto-
col was registered with Collaborative Approach to Meta-Analysis and Review of Animal Data
from Experimental Studies (CAMARADES)[13]. A summary of the methods is reported
below. Reporting of the full systematic review was in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[14], (S1 Table).
MEDLINE and Embase were searched via Ovid from 1st January 2004 to 10th April 2017
(see S2 Table for full search strategy). The citation lists of included studies were searched for
additional studies. In a deviation from the methodology published in the study protocol, due
to the large volume of studies retrieved from the primary searches, no further additional
sources were searched.
Two reviewers (PMB/SKS) independently screened titles and abstracts. Where eligibility
for inclusion could not be determined from the abstract the full manuscript was obtained and
reviewed for clarification. Any disagreements were resolved through discussion with a third
reviewer (JPB). Controlled trials evaluating an intervention to prevent or treat non-union and
measuring bone formation were eligible for inclusion; the focus of this review was to examine
preclinical therapies with clinical potential and so treatments which had already been evalu-
ated in a clinical study were excluded. Full inclusion and exclusion criteria were listed in the
previously published protocol and are summarised in Table 1. Relevant preclinical studies
evaluating therapies that had subsequently progressed to clinical trial were excluded, unless
the therapy was combined with a novel therapy.
After duplicates were removed, 5,171 records were identified in the literature search as
shown in the PRISMA flow diagram (Fig 1). After inclusion/exclusion criteria were applied
197 studies were included in the systematic review. The commonest single reason for study
exclusion (1,073 studies, 21%) was that the article described a therapy that had already pro-
gressed to clinical trial.
Table 1. Summary of study inclusion and exclusion criteria.
Inclusion Criteria
Types of studies Controlled trials
Unpublished and published works
Types of participants Mammalian model testing an intervention to treat or prevent fracture non-union
Induced co-morbidities
Intervention Interventions aim to:
• Prevent non-union
• Treat non-union
• Promote or accelerate healing of a bony defect
• Treat or ameliorate delayed union
Administered after formation of a bony defect
Established interventions in a novel vehicle
Comparator Control group described receiving:
• No treatment
• Current standard of care
• Alternative treatment
Outcome measures Quantifiable measure of bone formation through radiological and/or histological means
Exclusion Criteria
Types of studies Review articles
Types of participants Clinical trials
Intervention Any intervention that has subsequently progressed to clinical trial
https://doi.org/10.1371/journal.pone.0201077.t001
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Data extraction and risk of bias assessment
Data relating to the model, defect location and method of creation, length of survival, number
of animals included, outcome measures (radiological or histological) were extracted from
manuscripts.
Where incomplete data was provided in the manuscript authors were contacted for clarifi-
cation: of the 64 authors contacted, only 9 replied with the required information (14%).
Fig 1. PRISMA flow diagram for study inclusion/exclusion. Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA)
flow diagram detailing numbers of studies excluded and reasons at each stage of the review process.
https://doi.org/10.1371/journal.pone.0201077.g001
Preclinical therapies for fracture non-union
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Numerical data extraction from papers presenting results in graphical format only was per-
formed using ImageJ v.2.0 software (National Institute of Health, Bethesda, MD) using a stan-
dardised method[15, 16].
The Systematic Review Centre for Laboratory Animal Experimentation’s (SYRCLE) risk of
bias tool was used to assess risk of bias across all studies[17]. The SYRCLE tool assesses ten
domains across six types of bias: selection bias (sequence generation, baseline characteristics,
allocation concealment), performance bias (random housing, blinding), detection bias (ran-
dom outcome assessment, blinding), attrition bias (incomplete outcome data), reporting bias
(selecting outcome reporting) and other sources of bias. Risk of bias assessment was performed
by one author (PMB or SKS). Each domain was given a rating of high risk, low risk or unclear
where information was incomplete or not reported. These ratings were based on the signalling
questions designed to assist judgement, as detailed in the SYRCLE tool[17].
Analysis
Where studies reported sufficient data (numbers in intervention and control group, mean and
standard deviation), results for the most consistently reported measures (bone formation (%),
bone volume (mm3) or bone density (mg/cm3)) were represented in forest plots for illustrative
purposes. Results for the remaining studies were tabulated. Where several time-points were
reported, only the longest follow-up was considered.
Therapies were grouped into the following nine categories:
• Animal derivatives
• Plant extracts
• Minerals/elements/chemicals
• Pharmaceuticals
• Cells/tissues
• Vibration/motion
• Light/lasers
• Gases
• Human proteins/hormones
If a therapy related to more than one category, it was included in both it pertained to (e.g.
mesenchymal stem cells with insulin-like growth factor-1 was recorded in both the ‘cells/tis-
sues’ and ‘human proteins/hormones’ categories.) Combination therapies using both an estab-
lished therapy already in clinical trial with a novel preclinical therapy were again recorded in
both categories to which they pertained.
Results
The spectrum of potential treatments
The 197 included studies evaluated a total of 204 different interventions (Table 2). The objec-
tive of approximately half of all studies was to promote or accelerate healing of a bony defect
(103/197, 52%) or treat non-union (93/103, 47%), with further information available in S3
Table. The majority of therapies (179/204 (88%)) were only evaluated once, while five inter-
ventions (chitosan [18–23], adipose stromal cells [24–27], erythropoietin [28–31], vascular
endothelial growth factor [32–35] and SDF-1 [36–38]) were investigated by multiple studies
Preclinical therapies for fracture non-union
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(Table 3). Chitosan as a single therapy was evaluated by six studies: four of these found signifi-
cantly greater bone formation in the intervention group compared to control [18, 20–22], with
further detail in Table 3.
Risk of bias
Details necessary to assess risk of bias were vastly underreported, particularly with regard to
random housing, random outcome assessment (randomisation), sequence generation,
Table 2. Number of evaluations under investigation by category.
Group Number of evaluations included in tables Number of evaluations included in forest plots Total
Animal derivatives 27 5 32
Plant extracts 23 13 36
Minerals / elements / chemicals 25 7 32
Pharmaceuticals 16 13 29
Cells / tissues 32 18 50
Vibration / motion 2 5 7
Light / lasers 3 0 3
Gases 3 5 8
Human proteins / hormones 59 41 100
Total 190 107 297
Combination therapies are duplicated in all groups they pertain to, e.g. mesenchymal stem cells + vascular endothelial growth factor will be counted in “cells / tissues”
and “human proteins / hormones”.
Single therapies tested in multiple concentrations are counted more than once, e.g. Ngueguim 2012 evaluates two plant based therapies: both therapies are evaluated at
three different concentrations, thereby contributing 6 evaluations.
A total of 197 studies were included, investigating a total of 204 distinct therapies.
Total number of studies included in tables = 136, total number of studies included in forest plots = 61.
https://doi.org/10.1371/journal.pone.0201077.t002
Table 3. Most frequently evaluated therapies across all studies (n = 197).
Therapy Number of studies
evaluating therapy
Direction of effect
Chitosan 6 Four studies [18, 20–22] favoured intervention over
control.
One study [19] favoured control over intervention.
One study [23] showed no difference between
intervention and control.
Adipose stromal cells 4 Two studies [25, 27] favoured intervention over
control.
Two studies [24,26] showed no difference between
intervention and control.
Erythropoietin 4 Four studies [28–31] showed no difference between
intervention and control
Vascular endothelial
growth factor
4 Two studies [32, 35] favoured intervention over
control.
Two studies [33, 34] showed no difference between
intervention and control.
SDF-1 3 Two studies [36, 38] favoured intervention over
control.
One study [37] showed no difference between
intervention and control.
Therapies tested twice 40
Therapies tested once 179
https://doi.org/10.1371/journal.pone.0201077.t003
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blinding of outcome assessment and selective outcome reporting (Fig 2). Between 4 and 23%
of studies were judged to be at high risk of bias for a given criterion. No study reported details
for all ten domains of the SYRCLE tool.
The most consistently reported outcome measure was percentage bone formation in the
category of human proteins and hormones (Fig 3 [25, 28, 32, 36, 39–58]). Study findings across
all categories for bone formation, bone volume and bone density are shown in Fig 4, [23, 47,
51, 53, 54, 57, 59–77], Fig 5 [29, 37, 38, 78–86] and Fig 6 [87–91]). Table 4 ([92–105]) shows
the findings for the pharmaceutical therapies that could not be represented in forest plots, with
findings for the remaining categories available as supporting information (S4, S5, S6, S7, S8,
S9, S10 and S11 Tables).
In total 53 human protein and hormone therapy evaluations (30 in forest plots, 23 in tables,
53/100, 53%) reported statistically significant improvements in bone healing compared to the
control groups. Statistically significant improvements for the other categories were 50% animal
derivatives (16/32), 53% plant extracts (19/36), 55% minerals/elements/chemicals (18/33), 38%
pharmaceuticals (11/29), 54% cells/tissues (26/48), 30% vibration/motion (3/10), 100% light/
lasers (3/3) and 75% gases (6/8). In total, 135 separate therapy evaluations (135/204, 66%)
showed a significantly greater effect on healing of fracture non-union when compared to the
control. Only a minority of interventions (9/204, 4%) resulted in significantly less effect on
bone union than the comparator arm.
Meta-analysis
Substantial heterogeneity across studies in terms of type and site of defect, method of defect
creation, species, length of follow-up and method of outcome reporting precluded meta-
analysis.
Fig 2. Risk of bias analysis. Bias assessed as per the Systematic Review Centre for Laboratory Animal Experimentation’s (SYRCLE) tool for all
197 studies included.
https://doi.org/10.1371/journal.pone.0201077.g002
Preclinical therapies for fracture non-union
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Rats were the most common animal model, used in 105 studies (105/197, 53%), with the
calvarium being the commonest site of bony defect (71/197, 36%). Pigs, dogs, goats, rabbits
and mice were also used. Further detail on animal and defect location is given in Table 5. It
was not possible to determine the total number of animals used in 28 studies (28/197, 14%)
with further detail in S2 Table. Studies used both radiological and histological outcome mea-
sures, with follow-up times ranging from 1–30 weeks (Fig 7).
Regarding the defect, the majority of studies (75/197, 38%) did not report how the defect
was created. A bur was used in 51 studies (51/197, 26%), with other methods including drills
(14%), saws (12%), three-point bending (5%), drop weights or pendulums (3%), and being cut
with scissors (3%). The defect was explicitly stated as being critical in 75 studies (75/197, 38%)
Fig 3. Bone formation data for studies looking at interventions of human proteins and hormones or cells and tissues. Forest plot
illustrating mean difference in percentage of bone formation as measured by different histological or radiological measures. Abbreviations:
ASCs, adipose tissue stem cells; BMSCs, bone marrow stromal cells; CI, confidence interval; HS, heparan sulphate; LV-Wnt10b, lentivirus vector
encoding Wnt10b gene; MSCs, mesenchymal stem cells; OGP, osteogenic growth peptide; PRP, platelet rich plasma; PTH, parathyroid
hormone; SDF-1, stromal cell derived factor 1; VEGF, vascular endothelial growth factor; WMD, weighted mean difference.
https://doi.org/10.1371/journal.pone.0201077.g003
Preclinical therapies for fracture non-union
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and non-critical in 2 (2/197, 1%), with the remainder of studies (155/197, 79%) not providing
this detail. Ten studies (6%) cauterised or stripped the periosteum surrounding the osteotomy.
Only one third of studies (61/197, 31%) included sufficient data to permit illustration in for-
est plots (without quantitative pooling), due to insufficient reporting of outcome data, or use
of less commonly used outcome metrics.
Discussion
Fracture non-union is a common complication of a common condition [1–3]. This systematic
review highlights not only the range of research activity in this field but the poor quality of
contemporary animal research investigating this condition. Meta-analysis was not possible
due to the diverse and non-standardised nature of the preclinical research, range of outcome
measures and poor reporting of results. Despite there being a large amount of data– 204
Fig 4. Bone formation data for studies looking at interventions of vibration and motion, gases, minerals, elements and chemicals,
pharmaceuticals, animal derivatives or plant extracts. Forest plot illustrating mean difference in percentage of bone formation as measured by
different histological or radiological measures. Abbreviations: BMSCs, bone marrow stromal cells; CI, confidence interval; PRP, platelet rich
plasma; PTH, parathyroid hormone; VACC, vanadium absorbed by Coprinus comatus; WMD, weighted mean difference.
https://doi.org/10.1371/journal.pone.0201077.g004
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evaluations across 197 studies—it has not been possible to make a valid comparison between
any two studies nor draw firm conclusions regarding relative efficacies from different inter-
ventions and therefore identify those therapies that should be prioritised in translational
research.
When developing preclinical models of fracture non-union various factors need to be con-
sidered. Fundamentally these include the species of animal to be used and the anatomical loca-
tion of the fracture. Additionally, the type of fracture (transverse or segmental), whether it is
subsequently stabilised or not and whether or not the periosteum is stripped are all variables
that will affect the union rates of the fracture model. Finally, the delivery method of the therapy
under investigation, including the use of scaffolds and carriers, must also be considered. The
greater the number of differences that exist between model designs, the less reliably any differ-
ences in union rates can be attributed to the therapy under investigation alone, as model varia-
tions will act as confounders.
Fig 5. Bone volume data for studies looking at interventions of human proteins and hormones, cells and tissues, minerals, elements and
chemicals, pharmaceuticals or animal derivatives. Forest plot illustrating mean difference in cubic millimetre (mm3) of bone volume as
measured by different histological or radiological measures. Since none of the control groups healed, the increase in bone volume was set as 0
and the standard deviation as 0.0000001 in order to be able to illustrate those results in a forest plot using STATA. Abbreviations: BMP2, bone
morphogenetic protein 2; BMSCs, bone marrow stromal cells; CI, confidence interval; HA, hyaluronic acid; IGF-1, insulin growth factor-1;
MSCs, mesenchymal stem cells; OPG, osteoprotegerin; PI, proteasome inhibitor; SDF-1, stromal cell derived factor 1; VEGF, vascular
endothelial growth factor; wks, weeks; WMD, weighted mean difference.
https://doi.org/10.1371/journal.pone.0201077.g005
Preclinical therapies for fracture non-union
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In clinical practice the progression of a fracture to established non-union is multi-factorial,
with different types of non-union existing. The majority of primary research contained within
this systematic review failed to consider this variability during model development: though the
stated aim was to test a therapy designed to prevent or treat non-union, very few used proven
models of non-union. The poor fidelity to clinical situations further limits the utility of the pre-
clinical findings.
This systematic review used a methodologically rigorous approach to identifying, selecting
and appraising primary studies. There were however some deviations from the previously pub-
lished protocol; the authors chose to use the MEDLINE version of PUBMED to allow easier
duplication of the search strategy on OVID. The decision to limit the systematic review to only
these two primary databases was made due to the large volume of eligible studies included.
The authors judged it unlikely that the inclusion of a small number of additional studies identi-
fied through other sources would significantly alter any conclusions, particularly given the
variable and methodologically poor reporting of studies identified in the main databases.
Additionally, the large number of studies meant that the risk of bias assessment was performed
by one reviewer only for each study.
The studies included in this systematic review were limited by inadequate reporting of
methodological details and results. Applying the risk of bias tool developed by SYRCLE
showed that many risk of bias criteria were not reported and the rating of ‘unclear’ risk
of bias was most common. This in turn hampers interpretation of results. It is however in
line with the findings of previous studies which found poor reporting of randomisation
Fig 6. Bone density data for studies looking at interventions of human proteins and hormones, cells and tissues or plant extracts. Forest
plot illustrating mean difference in milligrams per cubic centimetre (mg/cm3) of bone density as measured by different histological or
radiological measures. Abbreviations: CI, confidence interval; GSK3, glycogen synthase kinase 3; WMD, weighted mean difference.
https://doi.org/10.1371/journal.pone.0201077.g006
Preclinical therapies for fracture non-union
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Table 4. Defect repair data for studies evaluating therapies based on pharmaceuticals (16 therapies, 14 studies).
Study Therapy Species Maximum length of
survival (days)
Outcome Overall
effect
Alic 2016 [92] Cilostazol Rats 21 No difference between groups at end of 21 days =
Baht 2017 [93] Nefopam Mice 21 Treatment with Nefopam resulted in fracture calluses that contained higher
proportions of bone and lower proportions of fibrous tissue
!
Bernick 2014
[94]
Lithium Rats 28 Fracture healing was maximised with low dose, later onset and longer
treatment duration of lithium, resulting in significantly greater yield torque
in the therapeutic group
"
Cai 2015 [95] Lithium Rabbits 84 New bone area for lithium containing mesoporous bioglass markedly higher
than that for lithium containing bioglass at 56 and 84 days
!
Cakmak 2015
[96]
Pentoxyfylline Rats 56 No bone growth in control or systemic pentoxyfylline only groups =
Cakmak 2015
[96]
Pentoxyfylline + iliac
crest autograft
Rats 56 Radiological bone union was observed in the iliac crest autograft and
systemic pentoxyfylline group compared to no new bone growth in the
control group
!
Del Rosario
2015 [97]
Simvastatin Rats 56 No significant difference between groups =
Donneys 2013
[98]
Deferoxamine Rats 40 Greater union rate in treatment group than in irradiated group, but both less
than control group
#
Fan 2017 [99] Phenamil Rats 86 Incomplete mandibular restoration was observed in the defect treated with
phenamil alone
?
Fan 2017 [99] Phenamil + BMP Rats 86 Addition of BMP to phenamil synergistically augmented bone healing,
resulting in almost complete bone healing
!
Ishack 2017
[100]
Dipyridamole Mice 56 Significant increase in percentage of bone regenerated in dipyridamole group
compared to control group
"
Kutan 2016
[101]
Doxycycline Rats 28 Osteogenesis in the test group was significantly higher than that of the
control group
"
Limirio 2016
[102]
Doxycycline
+ alendronate
Rats 15 Statistically greater bone density in therapeutic group compared to control
group at 15 days
"
Wada 2013
[103]
Salicylic acid Rats 84 Significantly higher new bone in defect in therapeutic group compared to
control group
"
Werkman
2006 [104]
Risedronate Rats 28 No significant difference between therapeutic and control groups =
Wixted 2009
[105]
Zileuton Mice 28 Net increase in callus size relative to control !
" indicates statistically significant effect on bone formation in trial therapy compared to control
! indicates greater bone formation in trial therapy compared to control, but the effect did not reach statistical significance
= indicates no difference in bone formation rates between the therapeutic or control groups
# indicates less effect on bone formation in trial therapy compared to control
? indicates results are unclear, and no effect size could be determined
https://doi.org/10.1371/journal.pone.0201077.t004
Table 5. Model of non-union by species and anatomical location.
Calvarium Femur Humerus Mandible Radius Rib Tibia Ulna Zygomatic arch Total
Pigs 2 2
Dogs 1 1 2
Goats 1 1
Rabbits 17 8 1 2 14 10 4 1 57
Rats 42 40 6 1 1 14 1 105
Mice 10 12 8 30
Total 71 60 1 8 16 1 34 5 1 197
https://doi.org/10.1371/journal.pone.0201077.t005
Preclinical therapies for fracture non-union
PLOS ONE | https://doi.org/10.1371/journal.pone.0201077 August 1, 2018 12 / 22
procedures and blinding of assessors in animal studies[106], despite multiple resources
for study design and reporting available to researchers[107–109]. Some omissions were
extremely basic, for example 11% of studies had to be excluded from the forest plots for not
stating whether their results were reported as mean with standard deviation, or standard
error of the mean, with authors failing to provide clarification when contacted. The use
of ± in methodological reporting without further explanation has previously been identified
as a persistent problem[110, 111].
To address the problems identified by this review, the authors recommend that the ortho-
paedic trauma community attempt to reach a consensus on preferred animal models of bone
healing similar to the standardisation of fracture classification with the OTA/AO/Muller sys-
tem[112]. Once a consensus on the standardisation of species, defect and outcome measure is
achieved, funding could be restricted to researchers using agreed models and study methodol-
ogy[113], and journals should similarly restrict publication to studies that would allow direct
comparison and insist on reporting results in detail. However, even if this were achieved, the
translatability of animal research into effective clinical trials remains controversial [114–116],
with even highly cited animal studies failing to translate into successful interventions in clinical
trials[117].
Fig 7. Bar graph demonstrating varied study methodology. Illustration of study-end point in weeks and outcome measure used by all 197
studies.
https://doi.org/10.1371/journal.pone.0201077.g007
Preclinical therapies for fracture non-union
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This systematic review describes the diverse range of treatments currently under investiga-
tion at the preclinical stage for the prevention or treatment of fracture non-union. These thera-
pies can be divided into nine broad treatment categories. Approximately 90% of interventions
were only evaluated by a single study, and only five were evaluated three or more times. Reli-
ance on a single study is problematic given the methodological limitations of the research and
when considered in the context of publication bias.
Publication bias is an established problem of clinical trials, and its prevalence in animal
studies is increasingly recognised[115, 118]. Failing to publish non-significant results of pre-
clinical research limits the ability of researchers to interpret the efficacy of a therapy in the
context of the wider literature. It is also unethical: subjecting animals to experiments without
publishing the results effectively wastes those animals. The majority of studies included in this
review (66%) reported significantly greater rates of bone healing in the therapeutic group com-
pared to the control group. While formal assessment of publication bias was not possible it is
reasonable to speculate that a bias against publication of negative or non-significant results
persists.
The variability across studies meant that no two studies from the 197 included in this review
were judged to be sufficiently similar across clinical and methodological parameters to allow
pooling of results in a meta-analysis. Only 31% of studies presented their results in sufficient
detail to be illustrated graphically in a forest plot. Not only does this preclude a rapid visual
comparison of results from different studies, but it is also indicative of a lack of detail in report-
ing scientific findings.
Heterogeneity is expected in systematic reviews of preclinical research. Indeed, it could
be argued that the aim of a systematic review in this field is to explore and demonstrate the
breadth of the evidence, the variability between studies and the consistency of any findings.
The generation of a precise pooled effect estimate through meta-analysis even where this is
deemed feasible may be of limited value given translatability issues. Yet in this review it was
mostly not possible to comment on the consistency of benefit of a particular intervention, as
they were mostly only explored in one or two studies.
This systematic review has defined the considerable range of therapies currently being
investigated at the preclinical phase for the treatment and prevention of fracture non-union.
Though some studies report statistically significant results for some therapies, high levels of
clinical and methodological heterogeneity and poor methodological quality and reporting
severely hamper the ability to prioritise therapies for translation into clinical trials. If the
orthopaedic trauma community were to collectively agree on a standardised animal model
for investigating this question, and standards for reporting of all results regardless of findings
were mandated, improved clinical treatments for fracture non-union will be developed more
efficiently.
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